Table I.
Baseline characteristics, both overall and according to background statin therapy* (safety population)
| Parameter | High-intensity statin (n = 580) | Low/moderate-intensity statin (n = 181) | No statin (n = 233) | All (n = 994) |
|---|---|---|---|---|
| Age [years] mean (SD) | 55.2 (11.6) | 55.3 (12.3) | 61.3 (10.4) | 56.6 (11.7) |
| Male, n (%) | 370 (63.8) | 112 (61.9) | 143 (61.4) | 625 (62.9) |
| BMI [kg/m2] mean (SD) | 28.4 (5.1) | 27.6 (4.7) | 27.3 (4.4) | 28.0 (4.9) |
| HeFH, n (%) | 436 (75.2) | 119 (65.7) | 81 (34.8) | 636 (64.0) |
| LDL-C [mmol/l] mean (SD) | 4.5 (1.4) | 4.8 (1.4) | 5.2 (1.9) | 4.8 (1.6) |
| Prior ezetimibe, n (%) | 383 (66.0) | 102 (56.4) | 71 (30.5) | 556 (55.9) |
*
High-intensity statin was defined as atorvastatin 40 or 80 mg, rosuvastatin 20 or 40 mg, or simvastatin 80 mg daily; low/moderate-intensity statin was defined as all other statins and/or doses.
BMI – body mass index, HeFH – heterozygous familial hypercholesterolemia, LDL-C – low-density lipoprotein cholesterol, SD – standard deviation.